OBJECTIVES: Many individuals with Alzheimer's disease (AD) experience behavioral and neuropsychiatric symptoms, which may cause caregiver distress and lead to the institutionalization of the patient. This analysis characterized behavioral symptoms and caregiver distress in trials of galantamine and their response to treatment. MATERIALS AND METHODS: Data were pooled from four randomized, placebo-controlled clinical trials of galantamine in patients with mild to moderate AD (three studies) or AD plus cerebrovascular disease (one study) (n = 2177). Behavior and associated caregiver distress were assessed in each study using the Neuropsychiatric Inventory (NPI) and NPI distress (NPI-D), respectively. RESULTS: After 5/6 months, but not after 3 months, NPI score was significantly improved with galantamine vs placebo (P = 0.013). The benefit was particularly pronounced in patients categorized as having advanced moderate AD. At 5/6 months, there was a numerical benefit of galantamine over placebo in terms of caregiver distress; the difference was statistically significant in patients with moderate or advanced moderate AD. CONCLUSIONS:Galantamine reduces behavioral symptoms in patients with mild to moderate AD, leading to reduced caregiver burden. The reductions were greatest in patients with moderate or advanced moderate disease.
RCT Entities:
OBJECTIVES: Many individuals with Alzheimer's disease (AD) experience behavioral and neuropsychiatric symptoms, which may cause caregiver distress and lead to the institutionalization of the patient. This analysis characterized behavioral symptoms and caregiver distress in trials of galantamine and their response to treatment. MATERIALS AND METHODS: Data were pooled from four randomized, placebo-controlled clinical trials of galantamine in patients with mild to moderate AD (three studies) or AD plus cerebrovascular disease (one study) (n = 2177). Behavior and associated caregiver distress were assessed in each study using the Neuropsychiatric Inventory (NPI) and NPI distress (NPI-D), respectively. RESULTS: After 5/6 months, but not after 3 months, NPI score was significantly improved with galantamine vs placebo (P = 0.013). The benefit was particularly pronounced in patients categorized as having advanced moderate AD. At 5/6 months, there was a numerical benefit of galantamine over placebo in terms of caregiver distress; the difference was statistically significant in patients with moderate or advanced moderate AD. CONCLUSIONS:Galantamine reduces behavioral symptoms in patients with mild to moderate AD, leading to reduced caregiver burden. The reductions were greatest in patients with moderate or advanced moderate disease.
Authors: Shefali Chaudhary; Simon Zhornitsky; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li Journal: Am J Alzheimers Dis Other Demen Date: 2022 Jan-Dec Impact factor: 2.632
Authors: Teresa Pardo-Moreno; Anabel González-Acedo; Antonio Rivas-Domínguez; Victoria García-Morales; Francisco Jose García-Cozar; Juan Jose Ramos-Rodríguez; Lucía Melguizo-Rodríguez Journal: Pharmaceutics Date: 2022-05-24 Impact factor: 6.525
Authors: Ilona Hallikainen; Anne M Koivisto; Teemu Paajanen; Asta Hiltunen; Pertti Karppi; Matti Vanhanen; Tarja Välimäki; Sanna-Kaisa Herukka; Hilkka Soininen; Tuomo Hänninen Journal: Dement Geriatr Cogn Dis Extra Date: 2012-05-05
Authors: T Möllers; L Perna; H Stocker; P Ihle; I Schubert; B Schöttker; L Frölich; J Bauer; H Brenner Journal: Epidemiol Psychiatr Sci Date: 2019-11-14 Impact factor: 6.892
Authors: Luis Felipe José Ravic de Miranda; Marilourdes do Amaral Barbosa; Patrícia Regina Henrique Peles; Patrícia Hilar Pôças; Pedro Augusto Lopes Tito; Rafael de Oliveira Matoso; Thiago Oliveira Lemos de Lima; Edgar Nunes de Moraes; Paulo Caramelli Journal: Dement Neuropsychol Date: 2013 Apr-Jun